EBS Stock Price, Chart, Stats & News

Emergent BioSolutions Inc.
Save
405.03M
Market cap
–
Current P/E
2.08x
Forward P/E
EBS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 47.19% |
Operating margin | 14.83% |
Pretax margin | 11.15% |
Net margin | 7.08% |
Effective tax rate | 36.47% |
ROA | 3.99% |
ROE | 9.59% |
D/E | 1.09x |
Interest coverage ratio | 0.74x |
EBS valuation
P/E | – |
P/S | 0.55x |
P/B | 0.81x |
P/CF | 2.49x |
P/FCF | 2.62x |
P/OCF | 2.49x |
PEG | -0.27x |
EV multiple | 0.22x |
About
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox.
Similar securities
Based on sector and market capitalization
Report issue











